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Abstract: Although “chest distress” is the most frequent complication in the aged with chronic 
atrial frbrillation (AF) in clinical practice, there are few data on the association between chronic 
AF and coronary artery disease (CAD) in the aged in terms of medical treatment and long-term 
outcome. We assessed coronary artery lesions in such patients and evaluated the efficacy of medi-
cal treatment in long-term follow-ups. Of 315 elderly patients (mean age: 77.39 ± 6.33 years) 
who had undergone coronary angiography for chest distress, 297 exhibited sinus rhythm (SR), 
whereas 18 patients exhibited chronic AF. Patients with AF were followed for 4.22 ± 2.21 years. 
Average diastolic blood pressure (DBP) of AF patients was observed to be markedly less than that 
of patients with SR (57.33 ± 6.87 mmHg vs 71.08 ± 10.54 mmHg, t-test: P , 0.01). Compared 
with SR patients, severe stenosis of the coronary artery in AF patients was reduced (73.06% vs 
44.44%, Chi-square test: P , 0.01). AF patients with chest distress had high CHADS2 score 
(3.72 ± 1.27), but only 33.3% patients received oral anticoagulants, and such patients had a 
significantly lower rate of revascularization (21.43% vs 55.63%, Chi-square test: P , 0.01), and 
higher rate of all-cause death (22.22% vs 4.38%, Chi-square test: P , 0.01) and thromboem-
bolism (16.67% vs 1.68%, Chi-square test: P , 0.01) in the long-term follow-ups compared 
with SR patients. Chest distress in the aged with AF was related to insufficient coronary blood 
supply that was primarily due to a reduced DBP rather than to occult CAD. Adequate and safe 
medical therapy was difficult to achieve in these patients. Such patients typically have a poor 
prognosis, and optimal therapeutic strategies to treat them are urgently needed.
Keywords: aging, atrial fibrillation, coronary artery disease, antithrombotic therapy, revascu-
larization, outcome
Introduction
Atrial fibrillation (AF) is a common arrhythmia that is strongly associated with age, 
and therein, its prevalence has increased due to the increasing size of the elderly 
population.1–3 According to recent data, the projected prevalence of AF in 2050 will 
increase to 7.56 million in the United States and will almost surpass 25 million by 
2045 in China.4,5 AF is associated with increased morbidity and mortality. Coronary 
artery disease (CAD) is also an increasing problem in the elderly population and leads 
to an increased risk for cardiac events in comparison with younger patients.6 Recently, 
more emphasis has been placed on the interaction of AF with CAD in elderly people. 
Several studies have investigated the prevalence and significance of   new-onset AF 
following acute myocardial infarction (MI);7,8 however, there are few data on the Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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  association between chronic AF and CAD in elderly patients 
in terms of medical treatment and long-term   outcome. 
Is occult CAD the main reason for “chest distress” in elderly 
AF patients? What is the clinical efficacy of practical medical 
treatment in elderly AF patients with chest distress vs sinus 
rhythm (SR) patients in the long-term follow-ups? And how 
can adequate and safe medical therapy be achieved in these 
patients?
There is a paucity of available data that can be used to 
guide the management of elderly chronic AF patients with 
chest distress. The present study assessed the coronary artery 
lesions and evaluated the long-term outcomes of AF in the 
aged with chest distress vs SR patients.
Methods
study population
The study was conducted at the General Hospital of the 
Chinese People’s Liberation Army. The study was approved 
by the local ethics committee. We reviewed patients 
of age $65 years who had undergone coronary artery 
angiography for chest distress at our hospital from 1998 
to 2009. Patients who had a pre-existing diagnosis of AF 
(International Classification of Diseases, Tenth Revision 
ICD-10 code I48) were included. CAD was defined as the 
presence of at least one lesion with $50% luminal stenosis 
as determined by coronary angiography.
In addition to evaluating the main clinical character-
istics, the following parameters were retrospectively ana-
lyzed: (1) clinical type of AF; (2) concomitant diseases; (3) 
coronary angiography; (4) the influence of CHADS2 score 
on antithrombotic treatment and revascularization. 
CHADS2 is an acronym of a scoring scheme used for 
estimating stroke risk, containing the following conditions 
of the patients: C (congestive heart failure), H (hyperten-
sion), A (age .75 years), D (diabetes), and S (prior stroke 
or transient ischemic attack, TIA);9 (5) clinical events in 
long-term follow-up, including all-cause death, MI, target 
lesion revascularization (TLR), thromboembolism, and bleed-
ing episodes. TLR was defined as a re-intervention that was 
driven by any lesion located in the stented vessel.   Indication 
for a repeat revascularization was based on angina symp-
toms, significant luminal stenosis (.50% diameter), and/or 
proven myocardial ischemia in the target vessel   territory. 
Indication for a repeat revascularization was based on 
angina symptoms, significant luminal stenosis (.50% 
diameter), and/or proven myocardial ischemia in the target 
vessel territory. Patients who were unable or unwilling to 
follow-up were not included.
statistical analysis
Continuous variables were tested for a normal distribution 
using the Kolmogorov–Smirnov test. The normally distrib-
uted continuous variables are shown as mean ± SD. Discrete 
variables are presented as frequencies (percentages). The dis-
crete variables were compared via either the Chi-square test, 
continuity correction, or Fisher’s test (when the 2 × 2 table 
had ,five patients). Comparison of the groups for continu-
ous variables was performed with the t-test for independent 
samples that are parametrically distributed. All P values 
were two-sided, and a P value of ,0.05 was considered to be 
statistically significant. Statistical analyses were performed 
using SPSS (v 18.0; SPSS, Inc, Chicago, IL).
Results
Patient characteristics
This study included 315 patients (312 men and 3 women) 
who underwent percutaneous coronary interventions (PCIs) 
from 1998 to 2009 and had detailed clinical records. Among 
these patients, 297 patients (294 men and three women) had 
an SR. In total, 18 patients (5.71%) with pre-existing AF were 
Table 1 Baseline characteristics of the study population
Characteristic Total samples  
(n = 315)
SR  
(n = 297)
AF  
(n = 18)
P value
Mean age, years (sD) 77.39 (6.33) 77.30 (6.39) 79.00 (5.28) 0.21
sex
  Male, n (%) 312 (99.05%) 294 (98.99%) 18 (100%) 1.00
  Female, n (%) 3 (0.95%) 3 (1.01%) 0 (0%) 1.00
Concomitant disease
  hypertension, n (%) 192 (60.95%) 179 (60.27%) 13 (72.22%) 0.31
  Diabetes, n (%) 85 (26.98%) 79 (26.60%) 6 (33.33%) 0.53
  ChF*, n (%) 99 (31.43%) 83 (27.95%) 16 (88.89%) 0.00
  stroke/TIA, n (%) 38 (12.06%) 35 (11.78%) 3 (16.67%) 0.88
Notes: *Continuity correction Chi-square test, P , 0.05. The P value represents a comparison of the sinus rhythm (SR) and atrial fibrillation (AF) groups.
Abbreviations: ChF, chronic heart failure; CAD, coronary heart disease; TIA, transient ischemic attack.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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Table 2 Clinical assessment of elderly patients with chest distress
Characteristic Total samples  
(n = 315)
SR  
(n = 297)
AF  
(n = 18)
P value
height, cm (sD) 169.81 (5.17) 169.76 (5.21) 170.61 (4.42) 0.44
Weight, kg (sD) 70.82 (9.0) 70.78 (9.10) 71.44 (7.58) 0.72
BMI, kg/m2 (sD) 24.53 (2.70) 24.53 (2.72) 24.55 (2.58) 0.96
Pulse rate, bpm (sD) 69.83 (9.62) 70.01 (9. 73) 66.83 (7.25) 0.09
heart rate, bpm (sD) 70.12 (9.74) 70.01 (9. 73) 71.89 (10.08) 0.45
sBP, mmhg (sD) 131.03 (17.31) 131.32 (16.90) 126.33 (23.23) 0.38
DBP*, mmhg (sD) 70.30 (10.83) 71.08 (10.54) 57.33 (6.87) 0.00
Notes: *t-test, P , 0.05. The P value represents a comparison of the sinus rhythm (SR) and atrial fibrillation (AF) groups.
Abbreviations: BMI, body mass index; sBP, systolic blood pressure; DBP, diastolic blood pressure.
identified, in addition to six cases of permanent AF, ten cases 
of paroxysmal AF, and two cases of persistent AF. Mean age 
of the AF patients was 79 years (range: 65 to 87 years), and 
mean duration of AF was 10.21 ± 6.5 years (range: 0.7 to 
27 years). The most frequent concomitant disease of AF with 
chest distress in the aged was heart failure (HF), followed by 
hypertension and diabetes mellitus (Table 1).
Average DBP of the investigated AF patients was 
lower than that of patients with SR (57.33 ± 6.87 mmHg vs 
71.08 ± 10.54 mmHg, t-test: P , 0.01) (Table 2).
Coronary angiography
The angiographic results obtained from elderly patients with 
AF in comparison with those obtained from patients with SR 
are shown in Table 3. A narrowing of .75% was present in 
44.44% of patients with AF and in 73.06% of patients with 
SR (Chi-square test: P , 0.01; Table 4).
revascularization and antithrombotic 
therapy
SR patients had a significantly higher rate of revasculariza-
tion than AF patients (55.63% vs 21.43%, P = 0.012), 136 
(51.12%) received stent, and 12 (4.51%) were treated with 
a coronary artery bypass graft. Most patients received a 
drug-eluting stent (DES). Antithrombotic medications in 
SR patients after stent implantation included lifelong aspirin 
(ASA) and clopidogrel 75 mg/day for 1 year, with a minimum 
recommended duration of 6 months in the DES and 1 month 
in the bare metal stent. Moreover, of the 18 patients with AF, 
seven (38.89%) were treated with both ASA and clopidogrel, 
five (27.78%) were prescribed a single antiplatelet drug (ASA 
or clopidogrel), and six (33.33%) received warfarin.
Influence of CHADS2 score  
on antithrombotic treatment
Based on the presence of concomitant diseases and a his-
tory of previous stroke or TIA, the mean CHADS2 score 
in AF patients was 3.72 ± 1.27. The distribution of the 
CHADS2 scores in these elderly patients with chest dis-
tress was as follows: 16.7% (3/18) = 2, 33.3% (6/18) = 3, 
22.2% (4/18) = 4, 16.7% (3/18) = 5, and 11.1% (2/18) = 6. 
  However, oral anticoagulant (OAC) was administered to only 
33.3% of the patients. The patient with a CHADS2 score of 
4 received triple therapy with OAC, ASA, and clopidogrel 
after implanting DES.
Long-term outcomes
All patients were followed for 4.22 ± 2.21 years (range: 
1–8 years) to ascertain the clinical outcomes. All-cause 
death (22.22% vs 4.38%, Chi-square test: P , 0.01) and 
Table 3 The number of vessels with coronary disease in elderly 
patients with chest distress
CAD in AF 
(n = 14)
CAD in SR  
(n = 275)
χ2 P value
single-vessel  
coronary  
disease (n, %)
4 (28.57%) 77 (28.0%) 0.00 0.96
Double-vessel 
coronary  
disease (n, %)
2 (14.29%) 57 (20.73%) 0.34 0.56
Multivessel  
coronary  
disease (n, %)
8 (57.14%) 141 (51.27%) 0.18 0.67
Abbreviations:  CAD,  coronary  artery  disease;  sr,  sinus  rhythm;  AF,  atrial 
fibrillation.
Table 4 Coronary artery stenosis in patients with different heart 
rhythms
AF  
(n = 18)
SR  
(n = 297)
χ2 P value
#50% (n, %) 4 (22.22%) 31 (10.44%) 2.39 0.12
50%–74% (n, %) 6 (33.33%) 49 (16.50%) 3.34 0.07
$75%* (n, %) 8 (44.44%) 217 (73.06%) 6.81 0.01
Notes: *Chi-square test, P , 0.05. The P value represents a comparison of the sinus 
rhythm (SR) and atrial fibrillation (AF) groups.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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Figure 1 Long-term outcome. 
Notes: *Continuity Correction Chi-square test, P , 0.05. The P value represents a comparison of the sr and AF groups.
Abbreviations: MI, myocardial infarction; TLr, target lesion revascularization; Be, bleeding events; TB, Thromboembolism. 
  thromboembolism (16.67% vs 1.68%, Chi-square test: 
P , 0.01) were higher in AF than SR patients. There 
were no significant difference in MI (11.11% vs 4.71%, 
P = 0.52), TLR (5.56% vs 7.74%, P = 1.00), or bleeding 
events (5.56% vs 2.02%, P = 0.87) between AF and SR 
patients (Figure 1).
Discussion
Chest distress in elderly patients with chronic AF is a 
common clinical problem faced by clinicians. The opti-
mal therapeutic strategy for such patients is based on the 
major cause of the myocardial ischemia. Our findings 
reveal that in the elderly population with chronic AF, 
chest distress might not be associated with severe coro-
nary stenosis. Elderly patients with chronic AF had lower 
occurrence of arterial narrowing (> 75%) than patients 
with SR. This observation agrees with those of   Androulakis 
et al, who found that patients with paroxysmal AF or persis-
tent AF with a duration .30 days and concomitant ischemic 
ST segment depression exhibited ST-segment changes that 
were not consistently associated with the presence of obstruc-
tive CAD, especially considering that approximately only 
one in three patients presented   angiographically   significant 
coronary lesions.10 In another study, Lau et al screened 3393 
patients with acute coronary syndrome (ACS), and observed 
that 149 (4.4%) patients had new-onset AF and 387 (11.4%) 
patients had previous AF. In contrast to cases of new-onset 
AF, a history of previous AF was less frequent in patients 
with ST-segment elevation MI and left main CAD.11 Further-
more, we also found that the average DBP in elderly patients 
with chronic AF was markedly less than that in patients with 
SR, which most likely explains the chest distress experienced 
by chronic AF patients due to an insufficient coronary blood 
supply caused by a reduced DBP. More specifically, it is well 
known that most of the coronary flow occurs during diastole, 
and that good autoregulation between perfusion pressures 
of 60 and 200 mmHg can help maintain normal coronary 
blood flow. When the coronary perfusion pressure decreases, 
the subendocardial flow decreases. A further decrease in 
pressure to ,60 mmHg will suppress midcardial layer 
autoregulation, and, furthermore, subepicardial regulation 
will eventually wane at pressures ,50 mmHg.12
AF patients with chest distress had high CHADS2 score 
(3.72 ± 1.27), but only about one-third of patients received 
OAC. And such patients had a significantly lower rate of 
revascularization. All-cause death and thromboembolism Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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were obviously higher in AF than in SR patients at an   average 
follow-up of 4.22 years. Similarly, Lau et al observed that 
ACS patients with previous histories of AF had greater 
mortality rates than those with SR at 12-month follow-up.11 
One reason is that the elderly patients with chronic AF had 
a greater incidence of HF than elderly patients with SR. 
A similar phenomenon was observed in the Pro.V .A. Study,13 
wherein patients with AF and low ejection fractions had the 
highest absolute risk for adverse cardiovascular outcomes.14 
An additional cause for it is that it is too difficult to achieve 
a sufficiently effective and safe antithrombotic therapy for 
this population after PCI. Halbfass et al found an 11.5% rate 
of major bleedings, a 5.3% rate of thromboembolic events, 
and a 2.7% rate of stent thromboses in the high-risk group 
of patients with AF and coronary stent implants.15 Triple 
antithrombotic therapy (clopidogrel, ASA, and OAC) seemed 
to be clearly superior to a combination of clopidogrel and 
ASA in the prevention of cardiovascular events;16,17 however, 
a high rate of major bleeding was observed in AF patients 
with triple antithrombotic therapy.18 The optimization of 
antithrombotic strategies in such patients is a delicate bal-
ance between the efficacy of these therapies and the bleeding 
risk. Based on the available evidence of the use, safety, and 
efficacy of the various antithrombotic agents, there are three 
suggested treatment strategies. (1) Triple therapy with OAC, 
ASA, and clopidogrel should be used for patients with a low-
risk of hemorrhage. (2) Implantation of drug-eluting stents 
should be avoided in patients with a high hemorrhagic risk 
due to the prolonged need for dual antiplatelet   administration. 
(3) For patients who are at risk for both thrombosis/throm-
boembolism and hemorrhage, bare metal stents are preferred, 
and a combination of clopidogrel and OAC should be used 
for 1 month before continuing to antithrombotic treatment 
with OAC.19,20
Conclusion
In conclusion, elderly AF patients with chest distress 
exhibited less frequent occurrence of CAD than SR patients. 
It was found that the chest distress observed in elderly 
patients with AF resulted from insufficient coronary blood 
supply due to a low DBP instead of from occult CAD. Such 
patients had high CHADS2 score (3.72 ± 1.27), but only 
about one-third of patients received OAC. A significantly 
lower rate of revascularization in AF patients was observed, 
while all-cause death and thromboembolism were obviously 
higher in the long follow-up. Antithrombotic therapy, espe-
cially after PCI, is a challenging problem in clinical practice, 
and optimal   therapeutic strategies are needed. Prospective, 
randomized, and larger population studies are needed to 
confirm our results and to derive practical guidelines that 
clinicians can use to manage elderly AF patients with chest 
distress.
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